Biosafety evaluation of culture-expanded human chondrocytes with growth factor cocktail: a preclinical study

Abstract The scarcity of chondrocytes is a major challenge for cartilage tissue engineering. Monolayer expansion is necessary to amplify the limited number of chondrocytes needed for clinical application. Growth factors are often added to improve monolayer culture conditions, promoting proliferation...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Maimonah-Eissa Al-Masawa, Wan Safwani Wan Kamarul Zaman, Kien-Hui Chua
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2020
Materias:
R
Q
Acceso en línea:https://doaj.org/article/9b3e3dd6ee074ad39451cc5a24c3fe18
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:9b3e3dd6ee074ad39451cc5a24c3fe18
record_format dspace
spelling oai:doaj.org-article:9b3e3dd6ee074ad39451cc5a24c3fe182021-12-02T12:33:05ZBiosafety evaluation of culture-expanded human chondrocytes with growth factor cocktail: a preclinical study10.1038/s41598-020-78395-y2045-2322https://doaj.org/article/9b3e3dd6ee074ad39451cc5a24c3fe182020-12-01T00:00:00Zhttps://doi.org/10.1038/s41598-020-78395-yhttps://doaj.org/toc/2045-2322Abstract The scarcity of chondrocytes is a major challenge for cartilage tissue engineering. Monolayer expansion is necessary to amplify the limited number of chondrocytes needed for clinical application. Growth factors are often added to improve monolayer culture conditions, promoting proliferation, and enhancing chondrogenesis. Limited knowledge on the biosafety of the cell products manipulated with growth factors in culture has driven this study to evaluate the impact of growth factor cocktail supplements in chondrocyte culture medium on chondrocyte genetic stability and tumorigenicity. The growth factors were basic fibroblast growth factor (b-FGF), transforming growth factor β2 (TGF β2), insulin-like growth factor 1 (IGF-1), insulin-transferrin-selenium (ITS), and platelet-derived growth factor (PD-GF). Nasal septal chondrocytes cultured in growth factor cocktail exhibited a significantly high proliferative capacity. Comet assay revealed no significant DNA damage. Flow cytometry showed chondrocytes were mostly at G0-G1 phase, exhibiting normal cell cycle profile with no aneuploidy. We observed a decreased tumour suppressor genes’ expression (p53, p21, pRB) and no TP53 mutations or tumour formation after 6 months of implantation in nude mice. Our data suggest growth factor cocktail has a low risk of inducing genotoxic and tumorigenic effects on chondrocytes up to passage 6 with 16.6 population doublings. This preclinical tumorigenicity and genetic instability evaluation is crucial for further clinical works.Maimonah-Eissa Al-MasawaWan Safwani Wan Kamarul ZamanKien-Hui ChuaNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 10, Iss 1, Pp 1-13 (2020)
institution DOAJ
collection DOAJ
language EN
topic Medicine
R
Science
Q
spellingShingle Medicine
R
Science
Q
Maimonah-Eissa Al-Masawa
Wan Safwani Wan Kamarul Zaman
Kien-Hui Chua
Biosafety evaluation of culture-expanded human chondrocytes with growth factor cocktail: a preclinical study
description Abstract The scarcity of chondrocytes is a major challenge for cartilage tissue engineering. Monolayer expansion is necessary to amplify the limited number of chondrocytes needed for clinical application. Growth factors are often added to improve monolayer culture conditions, promoting proliferation, and enhancing chondrogenesis. Limited knowledge on the biosafety of the cell products manipulated with growth factors in culture has driven this study to evaluate the impact of growth factor cocktail supplements in chondrocyte culture medium on chondrocyte genetic stability and tumorigenicity. The growth factors were basic fibroblast growth factor (b-FGF), transforming growth factor β2 (TGF β2), insulin-like growth factor 1 (IGF-1), insulin-transferrin-selenium (ITS), and platelet-derived growth factor (PD-GF). Nasal septal chondrocytes cultured in growth factor cocktail exhibited a significantly high proliferative capacity. Comet assay revealed no significant DNA damage. Flow cytometry showed chondrocytes were mostly at G0-G1 phase, exhibiting normal cell cycle profile with no aneuploidy. We observed a decreased tumour suppressor genes’ expression (p53, p21, pRB) and no TP53 mutations or tumour formation after 6 months of implantation in nude mice. Our data suggest growth factor cocktail has a low risk of inducing genotoxic and tumorigenic effects on chondrocytes up to passage 6 with 16.6 population doublings. This preclinical tumorigenicity and genetic instability evaluation is crucial for further clinical works.
format article
author Maimonah-Eissa Al-Masawa
Wan Safwani Wan Kamarul Zaman
Kien-Hui Chua
author_facet Maimonah-Eissa Al-Masawa
Wan Safwani Wan Kamarul Zaman
Kien-Hui Chua
author_sort Maimonah-Eissa Al-Masawa
title Biosafety evaluation of culture-expanded human chondrocytes with growth factor cocktail: a preclinical study
title_short Biosafety evaluation of culture-expanded human chondrocytes with growth factor cocktail: a preclinical study
title_full Biosafety evaluation of culture-expanded human chondrocytes with growth factor cocktail: a preclinical study
title_fullStr Biosafety evaluation of culture-expanded human chondrocytes with growth factor cocktail: a preclinical study
title_full_unstemmed Biosafety evaluation of culture-expanded human chondrocytes with growth factor cocktail: a preclinical study
title_sort biosafety evaluation of culture-expanded human chondrocytes with growth factor cocktail: a preclinical study
publisher Nature Portfolio
publishDate 2020
url https://doaj.org/article/9b3e3dd6ee074ad39451cc5a24c3fe18
work_keys_str_mv AT maimonaheissaalmasawa biosafetyevaluationofcultureexpandedhumanchondrocyteswithgrowthfactorcocktailapreclinicalstudy
AT wansafwaniwankamarulzaman biosafetyevaluationofcultureexpandedhumanchondrocyteswithgrowthfactorcocktailapreclinicalstudy
AT kienhuichua biosafetyevaluationofcultureexpandedhumanchondrocyteswithgrowthfactorcocktailapreclinicalstudy
_version_ 1718393875605749760